CURE Epilepsy
Meets Standards
Standards For Charity Accountability
Governance
-
Board Oversight
-
Board Size
-
Board Meetings
-
Board Compensation
-
Conflict of Interest
Measuring Effectiveness
-
Effectiveness Policy
-
Effectiveness Report
Finances
-
Program Expenses
-
Fundraising Expenses
-
Accumulating Funds
-
Audit Report
-
Detailed Expense Breakdown
-
Accurate Expense Reporting
-
Budget Plan
Fundraising & Info
-
Truthful Materials
-
Annual Report
-
Website Disclosures
-
Donor Privacy
-
Cause Marketing Disclosures
-
Complaints
CURE Epilepsy meets the 20 Standards for Charity Accountability.
Stated Purpose:
"to fund breakthrough research that will transform the lives of people with epilepsy as we lead the search for a cure."
Year, State Incorporated:
1998, IL
Also Known As:
Citizens United for Research in Epilepsy
CURE Epilepsy reports that it invests in research to understand the biology of epilepsy and raises awareness of the causes, needs, and safety plans for those with epilepsy and related seizure disorders. The organization funds research that focuses on Sudden Unexpected Death in Epilepsy (SUDEP), genetic and rare epilepsies, and Post-Traumatic Epilepsy (PTE), as well as through investigator-initiated grants.
For the year ended December 31, 2024, CURE Epilepsy's program expenses were:
| Research | $4,103,408 |
| Awareness | $1,089,563 |
| Total Program Expenses | $5,192,971 |
Chief Executive
Beth Lewin Dean, Chief Executive Officer
Compensation*
$369,481
Chair of the Board
Justin Gover
Chair's Profession / Business Affiliation
Former Chief Executive Officer, GW Pharmaceuticals
Board Size
16
Paid Staff Size
22
*2024 compensation includes annual salary and, if applicable, benefit plans, expense accounts, and other allowances.
Method(s) Used:
Direct mail appeals, Telephone appeals, Invitations to fund raising events, Grant proposals, Internet, Planned giving arrangements, Workplace Giving
Fundraising costs were 12% of related contributions. (Related contributions, which totaled $5,551,284, are donations received as a result of fundraising activities.)
This organization is tax-exempt under section 501(c)(3) of the Internal Revenue Code. It is eligible to receive contributions deductible as charitable donations for federal income tax purposes.
The following information is based on CURE Epilepsy's audited financial statements for the year ended December 31, 2024.
Source of Funds
| Contributions | $2,632,133 |
| Special events, net | $1,863,274 |
| Grants | $1,043,704 |
| Investment income | $650,101 |
| Other income | $19,524 |
| In-kind contributions | $12,173 |
| Total Income | $6,220,909 |
Programs: 84% Fundraising: 11% Administrative: 5%
| Total Income | $6,220,909 |
| Total expenses: | $6,184,753 |
| Program expenses | $5,192,971 |
| Fundraising expenses | $679,998 |
| Administrative expenses | $311,784 |
| Other expenses | $0 |
| Income in Excess of Expenses | $36,156 |
| Beginning Net Assets | $6,959,952 |
| Other Changes In Net Assets | $0 |
| Ending Net Assets | $6,996,108 |
| Total Liabilities | $3,693,856 |
| Total Assets | $10,689,964 |
Note: According to the organization's 2024 audited financial statements, CURE Epilepsy received in-kind contributions totaling $12,173 in the form of pro bono legal services.
An organization may change its practices at any time without notice. A copy of this report has been shared with the organization prior to publication. It is not intended to recommend or deprecate, and is furnished solely to assist you in exercising your own judgment. If the report is about a charity and states the charity meets or does not meet the Standards for Charity Accountability, it reflects the results of an evaluation of information and materials provided voluntarily by the charity. The name Better Business Bureau is a registered service mark of the International Association of Better Business Bureaus.
This report is not to be used for fundraising or promotional purposes.
